2. Academic Validation
  3. Multifunctional Nanoprobe Au@Gd-SiO2-HA-Lyp-1/DOX with Dual-Targeting Functions Derived from HA and LyP-1: Diagnostic and Therapeutic Potential for Tumor Lymphatic Metastasis

Multifunctional Nanoprobe Au@Gd-SiO2-HA-Lyp-1/DOX with Dual-Targeting Functions Derived from HA and LyP-1: Diagnostic and Therapeutic Potential for Tumor Lymphatic Metastasis

  • Biomacromolecules. 2024 Aug 12;25(8):4728-4748. doi: 10.1021/acs.biomac.3c01452.
Qingjie Chen 1,  Mengzhi Wan 2,  Lanlan Zhu 2,  Min Hu 2,  Luxia You 2,  Fei Xu 2,  Jing Zhou 2
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
  • 2 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang 330006, China.
PMID: 39058483 DOI: 10.1021/acs.biomac.3c01452
Abstract

To address lymphatic metastasis in lung Cancer, we developed the Au@Gd-SiO2-HA-LyP-1 nanoprobe, assessing its diagnostic and therapeutic capabilities. This nanoprobe integrates a Au core with a Gd-SiO2 shell and dual-targeting HA-LyP-1 molecules. We evaluated its size, shape, and functional properties using various characterization techniques, alongside in vivo and in vitro toxicity tests. The spherical nanoprobes have a 50 nm diameter and contain 1.37% Gd. They specifically target lymphatic metastasis sites and tumor cells, showing enhanced MRI contrast and effective, targeted DOX delivery with reduced normal tissue toxicity. The Au@Gd-SiO2-HA-LyP-1 nanoprobe is a promising tool for diagnosing and treating lung Cancer lymphatic metastasis, featuring dual-targeting and superior imaging capabilities.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P2526A
    99.87%, LyP-1 (8 weeks) shows a remarkable reduction in plaque formation and plaque occupation rates in the LyP-1-treated group. In addition, a higher apoptotic rate in macrophages released from hypoxic plaques is observed after the treatment of LyP-1when compared to control peptide[1].
    The LyP-1 peptide is labeled with a near-infrared fluorophore (Cy5.5) for optical imaging.
    At days 3, 7, 14 and 21 after inoculation with 4T1 cells, tumor-bearing BALB/C mice is injected Cy5.5-LyP-1 (0.8 nmol) through the middle phalanges of the upper extremities of the tumor-bearing mice. The fluorescence intensities were 0.024, 0.038, 0.048 and 0.106×106 photon/cm2/sec respectively at days 3, 7, 14 and 21 after tumor cell inoculation, which are 1.02, 1.63, 2.04, and 4.52-fold higher than in the contralateral LNs. Cy5.5-LyP-1 staining in LNs co-localized with LYVE-1, suggesting lymphatics-specific binding of LyP-1 peptide[1].